Martin NM, Dayyeh BKA, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008; 14(28): 4573-4575 [PMID: 18680242 DOI: 10.3748/wjg.14.4573]
Corresponding Author of This Article
Raymond T Chung, MD, Gastroin-testinal Unit, Massachusetts General Hospital, WRN 1007, 55 Fruit Street, Boston, MA 02114, United States. rtchung@partners.org
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nicole M Martin, Barham K Abu Dayyeh, Raymond T Chung, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
ORCID number: $[AuthorORCIDs]
Author contributions: Martin NM, Abu Dayyeh BK and Chung RT wrote and analyzed the paper; Chung RT conceived the paper.
Correspondence to: Raymond T Chung, MD, Gastroin-testinal Unit, Massachusetts General Hospital, WRN 1007, 55 Fruit Street, Boston, MA 02114, United States. rtchung@partners.org
Telephone: +1-617-7247562
Fax: +1-617-7265895
Received: April 12, 2008 Revised: July 15, 2008 Accepted: July 22, 2008 Published online: July 28, 2008
Abstract
Anabolic steroid abuse is common among athletes and is associated with a number of medical complications. We describe a case of a 27-year-old male bodybuilder with multiple hepatic adenomas induced by anabolic steroids. He initially presented with tumor hemorrhage and was treated with left lateral hepatic segmentectomy. Regression of the remaining tumors was observed with cessation of steroid use. However, 3 years and a half after his initial hepatic segmentectomy, he presented with recurrent tumor enlargement and intraperitoneal hemorrhage in the setting of steroid abuse relapse. Given his limited hepatic reserve, he was conservatively managed with embolization of the right accessory hepatic artery. This is the first reported case of hepatic adenoma re-growth with recidivistic steroid abuse, complicated by life-threatening hemorrhage. While athletes and bodybuilders are often aware of the legal and social ramifications of steroid abuse, they should continue to be counseled about its serious medical risks.
Anabolic steroid abuse is common among athletes and is associated with a number of medical complications[1–3]. Reported hepatic complications include cholestasis, elevation of aminotransferases, jaundice, benign hepatic adenomas, and rare cases of hepatocellular carcinoma[4–6]. Histologic findings include peliosis hepatis, a lesion characterized by hepatic sinusoidal dilatation that is often cystic[78]. Rupture of these cysts can cause fatal internal hemorrhage[9]. We report the first case of adenoma re-growth and hemorrhage after relapse of androgen abuse.
CASE REPORT
A 27-year-old man with a 5-year history of anabolic steroid abuse presented to the emergency room with 2 d of midepigastric pain and nausea. His only medications were oral androstenedione and intramuscular nandrolone. He was a police officer and competitive bodybuilder. He denied use of alcohol, tobacco, and intravenous drugs. Physical examination disclosed midepigastric tenderness and tender hepatomegaly. Laboratories were notable for 2.2 mg/dL total bilirubin, 1.3 mg/dL direct bilirubin, 2457 U/L ALT, 431 U/L AST, and 275 U/L alkaline phosphatase. Hematocrit was 50.5%. Abdominal computed tomography (CT) on admission showed a round, heterogeneous-appearing 9.9 cm × 9.6 cm mass in the left lobe of the liver. Magnetic resonance imaging (MRI) with gadolinium contrast demonstrated multiple hepatic masses, the largest of which measured 10.6 cm ×10.6 cm. The largest mass had an enhancing capsule and demonstrated signal heterogeneity, characteristic of an adenoma with intralesional hemorrhage (Figure 1A). The patient underwent left lateral hepatic segmentectomy with open cholecystectomy. Pathologic examination revealed an adenoma with peliosis hepatis, 25 cm in diameter. The patient was instructed to discontinue steroid use. On MRI 3 mo later, the adenomas appeared 40% smaller (Figure 1B). The patient subsequently resumed oral androstenedione only.
Figure 1 T1-weighted magnetic resonance imaging (MRI) of multiple hepatic adenomas.
A: MRI at initial presentation demonstrates a heterogeneous-appearing, well-circumscribed mass measuring 10.6 cm x 10.6 cm in segments 2 and 3 of the liver and several smaller masses in the right liver. The largest mass has an enhancing capsule and demonstrates areas of internal T1 hyperintensity and hypointensity, as well as T2 hyperintensity, characteristic of an adenoma with intralesional hemorrhage; B: Three months after left lateral segmentectomy and steroid cessation, the lesions in the right liver appear approximately 40% smaller and enhance more homogeneously on T1-weighted MRI, indicating regression. Images have been electronically adjusted to illustrate lesions.
Approximately 3 years and a half after his first presentation, the patient returned to the emergency room with sudden-onset, right-upper quadrant pain in the setting of recurrent injection nandrolone use 6 wk earlier. Vital signs were within normal limits, and there was tender hepatomegaly. Laboratories were notable for ALT 625 U/L, AST 398 U/L, and normal alkaline phosphatase and total bilirubin. Prothrombin time (PT) was 13.1 s; international normalized ratio (INR) was 1.1. The hematocrit was 38.7%. Abdominal CT revealed several lesions in the right lobe of the liver, the largest of which had increased in size to 7.7 cm × 7.2 cm and demonstrated intralesional hemorrhage, accompanied by a subcapsular hematoma and intraperitoneal hemorrhage. CT angiogram on hospital day 2 showed no contrast extravasation, but the hematocrit dropped to 24.9%. On hospital day 3, the right upper quadrant pain worsened, and he became tachycardic. Repeat abdominal CT showed expansion of the hematoma, with new anterior subcapsular and subphrenic components (Figure 2). The hematocrit was 24.4%. Because of his limited hepatic reserve and ongoing steroid abuse, he was felt to be a poor candidate for either hepatic resection or liver transplantation. He, therefore, underwent angiographic embolization of the accessory right hepatic artery. Four units of packed red blood cells were transfused. The serum ALT exceeded 10000 U/L after the procedure but declined over several days. After transient oliguric renal failure, he was discharged to home on post-procedural day 5.
Figure 2 Abdominal CT at second presentation with abdominal pain after resumption of steroid abuse.
A heterogeneous-appearing, right hepatic mass measuring 7.2 cm × 7.7 cm and a large subcapsular hematoma are seen, indicating that one of the hepatic adenomas has enlarged since the previous presentation and has hemorrhaged spontaneously. Image has been electronically altered.
DISCUSSION
We report a rare case of hepatic adenoma regrowth with recidivistic steroid abuse, complicated by life-threatening hemorrhage. This case underscores the potentially life-threatening complications of anabolic steroid abuse, and calls for a high index of suspicion among health care providers for hepatic complications if a history of steroid use is elicited.
The risk of androgen-associated liver tumors appears to correlate with the cumulative androgen dose and the potency of the steroid used[10]. Our patient self-administered both oral androstenedione, which has relatively weak androgenic potential, and parenteral nandrolone, which is particularly potent due to C10 hydroxylation. Since androstenedione has not been associated with liver tumors, it is likely that the nandrolone promoted development of his hepatic adenomas. This is consistent with the recurrence of his symptoms soon after resumption of nandrolone.
Both nandrolone and androstenedione have been classified as Schedule III controlled substances in recognition of their abuse potential[1112]. Despite these legal restrictions, anyone can still obtain these drugs with little difficulty over the Internet.
By resuming anabolic steroid consumption after his first hospitalization, our patient clearly demonstrated a pattern of substance abuse. Risk factors for anabolic steroid abuse in male bodybuilders include body-image disturbances, history of childhood conduct disorder, and poor father-son relationships[13]. Had our patient’s condition deteriorated and necessitated consideration of liver transplantation, he would have been required to demonstrate a commitment to abstinence from steroids, in a manner analogous to the alcoholic patient[14].
Patients and physicians must be reminded that the sequelae of anabolic steroid abuse are life threatening. While athletes and bodybuilders are often aware of the legal and social ramifications of steroid abuse, they should also be counseled about its serious medical risks. In the context of an addictive behavior pattern, assiduous surveillance for neoplasms should also be undertaken.
Footnotes
Peer reviewers: Dr. Toru Ikegami, Department of Surgery
and Science, Kyushu University, 3-1-1 Maidashi, Higashiku,
Fukuoka 812-8582, Japan; Osman C Ozdogan, Associate
Professor, Department of Gastroenterology, Liver Unit,
Marmara University School of Medicine, Istanbul 34662,
Turkey
Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids.Pediatr Clin North Am. 2007;54:677-690, x.
[PubMed] [DOI][Cited in This Article: ]
Curry LA, Wagman DF. Qualitative description of the prevalence and use of anabolic androgenic steroids by United States powerlifters.Percept Mot Skills. 1999;88:224-233.
[PubMed] [DOI][Cited in This Article: ]
Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain.Int J Sports Med. 1997;18:557-562.
[PubMed] [DOI][Cited in This Article: ]
Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids.Clin Gastroenterol Hepatol. 2007;5:809-812.
[PubMed] [DOI][Cited in This Article: ]
Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature.Br J Sports Med. 2005;39:e27.
[PubMed] [DOI][Cited in This Article: ]
Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids.Liver. 1992;12:73-79.
[PubMed] [DOI][Cited in This Article: ]
Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996.Clin Ther. 1997;19:383-404; discussion 367-368.
[PubMed] [DOI][Cited in This Article: ]
Schedules of controlled substances. Code of federal regulations, Title 21, Vol. 9, ChapterII, Part 1308. U.S. Food and Drug Administration, 2005.
Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=130 &show FR=1.
[PubMed] [DOI][Cited in This Article: ]
FDA warning on androstenedione (andro). National Center for Complementary and Alternative Medicine, 2004.
Available from URL: http://nccam.nih.gov/health/alerts/androstenedione/consumeradvisory.htm.
[PubMed] [DOI][Cited in This Article: ]
Kanayama G, Pope HG, Cohane G, Hudson JI. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study.Drug Alcohol Depend. 2003;71:77-86.
[PubMed] [DOI][Cited in This Article: ]
Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH. Guidelines for the referral and management of patients eligible for solid organ transplantation.Transplantation. 2001;71:1189-1204.
[PubMed] [DOI][Cited in This Article: ]